Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Q: What type of study is this?

This is a In Vitro Study study.

Mireia Uribe‐Herranz; Aina Oliver‐Caldés; Neus Martínez-Micaelo; Marta Español‐Rego; Maria Val-Casals; Roberto Martínez-Soler; Elisa Rubio-García; Valeria Brunello; Erik Z. Mihelic; Nela Klein-González; Daniel Benítez‐Ribas; Núria Amigó; Andrea Vergara; Valentín Ortiz‐Maldonado; Luis Gerardo Rodríguez‐Lobato; Julio Delgado; Iñaki Ortiz de Landazuri; Verónica González‐Calle; Valentín Cabañas; Beatriz Martín-Antonio; Lorena Pérez-Amill; Juan Luis Reguera; Paula Rodríguez‐Otero; Bruno Paiva; Joaquín Martínez‐López; María‐Victoria Mateos; Mariona Pascal; Álvaro Urbano‐Ispizua; Europa Azucena González‐Navarro; Carlos Fernández de Larrea; Manel Juan

doi:10.1158/2643-3230.30040927

September 3, 2025Open Access

Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

View Full Paper

Ask AI

Bookmark

Share

Key Points

Supplementary Figure S10 shows phenotypic details of CAR T-cells, specifically the role of succinate supplementation.
Analysis includes CD4+ naive and terminally differentiated T cells alongside measurements of exhaustion levels.
This investigation employs in vitro characterization of CAR T-cells using specified metabolic factors.
Insights may enhance understanding of CAR-T treatment outcomes in myeloma, supporting tailored therapies.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Supplementary Figure illustrates phenotypic traits of CAR T-cells, highlighting immune and metabolic aspects.

Abstract

upplementary Figure S10 provides a phenotypic characterization of in vitro expanded CAR T-cells that were supplemented with succinate. This includes an analysis of CD4+ naive and terminally differentiated effector T cells, as well as CD4+ T-cell exhaustion levels.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Uribe‐Herranz et al. (2025) studied this question.

synapsesocial.com/papers/68c187339b7b07f3a0611a27 https://doi.org/10.1158/2643-3230.30040927

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 10 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading